Drug Type Biosimilar, Monoclonal antibody |
Synonyms CMAB 015, CMAB-015, CMAB015 |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 3 | CN | 30 May 2024 | |
Ankylosing Spondylitis | Phase 1 | CN | 06 Feb 2023 | |
Arthritis, Psoriatic | IND Approval | CN | 24 May 2022 |